Schroder Investment Management Group
TGTX icon

Schroder Investment Management Group’s TG Therapeutics TGTX Stock Holding History

Schroder Investment Management Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-79,959
Closed -$2.94M – 1211
2025
Q3 		$2.94M Buy
+79,959
New +$2.63M ﹤0.01% 858

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Schroder Investment Management Group's TGTX Position: Q4 2025 in Review

Schroder Investment Management Group sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 79,959 shares — an estimated $2.94M sold.

Schroder Investment Management Group first reported a position in TGTX in Q3 2025 and held it in 1 quarter. The position peaked at $2.94M in Q3 2025. 352 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • Schroder Investment Management Group reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Schroder Investment Management Group sold 79,959 TG Therapeutics shares in Q4 2025, an estimated $2.94M.
  • Schroder Investment Management Group first reported a position in TG Therapeutics in Q3 2025 and held it in 1 quarter.
  • Schroder Investment Management Group's TG Therapeutics position peaked at $2.94M in Q3 2025.
  • 352 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Schroder Investment Management Group's 13F filing for Q4 2025, filed 13 Feb 2026.